ADC Therapeutics (ADCT)
In a report issued on June 24, Leonid Timashev from RBC Capital maintained a Hold rating on ADC Therapeutics, with a price target of $2.00. The company’s shares closed last Friday at $1.02.
According to TipRanks.com, Timashev is a 5-star analyst with an average return of 24.2% and a 60.7% success rate. Timashev covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Praxis Precision Medicines, and Perspective Therapeutics.
ADC Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $5.67, a 455.9% upside from current levels. In a report issued on June 9, TipRanks – PerPlexity also reiterated a Hold rating on the stock with a $0.99 price target.
See today’s best-performing stocks on TipRanks >>
